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Abstract
Objective: To evaluate the diagnostic yield of magnetic cortical stimulation with the triple stimulation technique (TST) to
identify upper motor neuron (UMN) involvement in patients suspected of having ALS. Methods: Fifty-nine patients were
recruited to undergo TST in addition to the standard work-up for suspected motor neuron disease. TST combines
transcranial magnetic stimulation of the motor cortex with collision studies, which results in a higher sensitivity in detecting
UMN involvement. Primary outcome was the number of abnormal TST results in patients with possible ALS. The
positivity rate was converted to the number needed to test with TST (NN-TST) for one extra diagnosis of ALS. Results:
Fifty patients underwent TST. In the total group (n59), 18 patients had a motor neuron disorder but did not fulfil criteria
for ‘probable’ or ‘definite’ ALS. In four of these patients TST was abnormal (NN-TST, 4.5). One TST was erroneously
interpreted as abnormal. TST findings were normal in inclusion body myositis and peripheral nerve disorders. Conclusion:
This prospective and blind study confirms open studies of TST in the evaluation of ALS. We suggest that TST can be used
to arrive at a diagnosis of ‘probable’ or ‘definite’ ALS in patients lacking UMN signs in the upper extremities.
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Introduction
Amyotrophic lateral sclerosis is the neurodegenera-
tive disorder defined by progressive loss of motor
neurons in the motor cortex, brainstem, and spinal
cord (1). The diagnosis requires signs of upper
and lower motor neuron (UMN, LMN) loss, with
diagnostic certainty depending on the extent of signs
(2,3). The spread of abnormality to the different
regions of the body, defined in the El Escorial and
Airlie House criteria of diagnostic certainty, corre-
lates negatively with the number of diagnostic errors
(46). However, the classification is not related to
severity of the disease, as clearly indicated by the fact
that survival is comparable in ‘possible’ and ‘defi-
nite’ ALS (7). In the early diagnosis of ALS a change
from ‘possible’ to ‘probable’ ALS is relevant in the
first place because a clear diagnosis is important for
the patient and may improve communication of the
diagnosis (8,9). Secondary to a clear diagnosis,
neuroprotective therapy with riluzole can be started
early and treatment trials may be more successful
before neurodegeneration is widespread (7,10,11).
EMG can supplement clinical evaluation in the
detection of LMN deficits when diagnosing ‘prob-
able laboratory supported’ ALS, and further revision
of criteria has been proposed recently (12). The
application of the Awaji algorithm, which puts more
emphasis on the EMG in general and fasciculation
potentials in particular, improves diagnosis of LMN
abnormalities (13). However, the detection of UMN
deficits is currently based on clinical examination
alone. Transcranial magnetic stimulation may be
used to measure the function of UMN, but the most
frequently used measures are not very sensitive for
UMN deficits that are not clinically apparent.
Therefore, such techniques are not currently men-
tioned in diagnostic criteria (12,14). For diagnostic
purposes, the limiting factor is the large variation of
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motor evoked potentials (MEPs) within and be-
tween subjects. This variation is due not to sub-
maximal stimulation, but to the variable timing of
action potentials resulting in dispersion and phase
cancellation (15). Magistris et al. combined tran-
scranial magnetic stimulation with a collision tech-
nique that solves several of these problems with
amplitude measurements. With their triple stimula-
tion technique (TST), response amplitude directly
reflects the motor units and muscle fibres that can be
activated from the cortex. Reference values for TST
have a narrow range that results in higher sensitivity
in the detection of UMN involvement in a number
of central motor disorders, including ALS (16,17).
TST results correlate to some extent with the
severity of the UMN deficit and are more often
abnormal in patients with ‘definite’ or ‘probable’
ALS than in patients with ‘possible’ ALS (17,18). In
patients already diagnosed with ALS based on signs
in another region, TST may identify a previously
undetected abnormality of the UMN (16,1820).
On the basis of these results, it has been suggested
that TST can increase diagnostic certainty in ALS,
but to date the method has not been evaluated in a
prospective study.
We expected that TST would detect UMN
deficits in some patients in whom muscle tone and
reflexes in the upper extremity were normal on
clinical evaluation. Thus, TST findings, in combina-
tion with other signs and findings, may increase
diagnostic certainty, for example by grading up from
‘possible’ ALS to ‘probable’ ALS. In analogy to a
therapeutic trial, we calculated the ‘number needed
to test’ (21,22) to increase the diagnostic certainty in
one patient. The Standards for Reporting of Diag-
nostic accuracy (STARD) checklist was applied (23).
Methods
Patients
All patients referred to our tertiary neuromuscular
centre for evaluation of suspected motor neuron
disorders were eligible for inclusion in the study.
Motor neuron disease had to be considered in the
differential diagnosis, but not necessarily as the most
likely diagnosis. Exclusion criteria were seizures, and
metallic or electronic implants. All patients gave
informed consent. The study protocol was approved
by the local committee on research involving human
subjects.
Triple stimulation technique: set-up
For a complete theoretical and physiological back-
ground of the method we refer to the initial report
by Magistris et al. (15). Briefly, the first magnetic
stimulus induces action potentials in the cortex that
travel along the corticospinal tract and the peripheral
nerve. The other two stimuli, applied at the wrist
and at Erb’s point, are set up to quantify the result of
the first stimulus and to remove any dispersion.
Comparison of TST after cortical stimulation (TST
test) with that after Erb’s stimulation (TST control)
gives a direct estimate of UMN function. In the
following, we give the full technical details of our
implementation.
Self-adhesive electrodes (2222 mm Ag/AgCl,
Kendall H69P, Tyco Healthcare, Mansfield, MA,
USA) were placed at the motor point of the abductor
digiti minimi muscle and at the proximal phalanx of
the little finger. The EMG signal was amplified (250x,
Hydiak 693 DC/AC, EKIDA, Helmstadt, Germany),
filtered (103000 Hz), and digitized (10 kHz, 0.6 mV/
bit, CED Power 1401, Cambridge Electronic Design,
Cambridge, UK). Data acquisition, on-line visualiza-
tion, and stimulus timing were controlled with Spike2
software. Patients received visual feedback of the
baseline-corrected, rectified, and smoothed (100 ms
moving average) EMG at 200 ms/cm. Post-stimulus
data were displayed at 2.5 ms/cm (050 ms). Default
display gain was 3 mV/cm for adjustment of ampli-
tude markers and 200 mV/cm for the placement of
latency markers.
For peripheral nerve stimulation, a pair of self-
adhesive electrodes (3M Red Dot 2271, 3M Neder-
land, Zouterwoude, NL) was placed with the cathode
just proximal to the wrist over the ulnar nerve and the
anode medial and slightly proximal to it. The brachial
plexus was stimulated with large electrodes (5
4.5 cm, Thymapad ECT stimulus electrodes, So-
matics LLC, Lake Bluff, IL, USA) with the cathode
at Erb’s point and the anode at the scapula (24).
Electrodes were connected to constant current sti-
mulators (DS7A and DS7AH, Digitimer, Welwyn
Garden City, UK). By using a high-voltage stimu-
lator, supra-maximal stimulation was achieved with a
pulse duration of 0.1 ms. The motor cortex was
stimulated with a magnetic stimulator (Magstim 200,
Magstim, Witland, UK) connected to a 90-mm
circular coil centered above the vertex. Stimulation
intensity was 80% or 100% of maximum stimulator
output.
Triple stimulation technique: measurement protocol
During the measurements, the subject was lying on a
bed in supine position. To avoid movement artifacts,
the fingers were fixed with tape. The measurements
started with three recordings of maximum voluntary
abduction of the little finger, with the patients
receiving EMG feedback. The highest stable ampli-
tude was selected and 20% of the maximum EMG
was calculated as the target level for tonic voluntary
contraction. Supra-maximum stimulation intensity
was adjusted for ulnar nerve stimulation and prox-
imal stimulation during rest. The onset latency of
the compound muscle action potential (CMAP) was

































































measured. Its amplitude was measured from base-
line to negative peak and was required to exceed
2.0 mV.
During tonic contraction at 20% maximum
EMG, three to five magnetic stimuli were given
and the MEP was recorded. The latency of the MEP
was measured. The absence of a MEP in response to
cortical stimulation was considered as abnormal,
equivalent to an abnormal TST result and indicative
of a UMN lesion.
To achieve appropriate collision of action po-
tentials, the timing of TST was automatically
adjusted according to the conduction time of the
patient. Delay I was calculated as the difference
between MEP latency and distal motor latency.
Delay II was the difference between CMAP latency
in response to Erb’s points stimulation and distal
motor latency. As defined by Magistris et al., distal
motor latency was rounded up to the next milli-
second, while MEP latency and Erb latency were
rounded down to the nearest millisecond. The first
and the last TST trials were given as TST control
stimulations. In these trials, Erb’s stimulation was
followed after delay II by wrist stimulation and then
again by Erb’s stimulation after delay II. TST test
stimulation consisted of motor cortex stimulation,
wrist stimulation after delay I, and Erb’s stimula-
tion after delay II. Three TST test trials were
performed, with the magnetic stimulator set to
80%, 100%, and 100% of maximum stimulator
output. No threshold measurements were per-
formed. All five trials were superimposed to check
for signal quality, movement artifacts, and consis-
tent supramaximal stimulation (Figure 1).
As voluntary pre-activation may be required
for maximum activation of the hand muscles, all
TST trials were performed with 20% voluntary
contraction. A sandbag was used to avoid changes
in hand position between trials. The number of
TST trials was predefined to exclude that the
investigation was repeated until the investigator
was ‘satisfied’.
The amplitude of the TST response was mea-
sured from baseline to the negative peak. TST
amplitude ratio was defined as the ratio between
the maximum of three TST test amplitudes divided
by the maximum of two TST control amplitudes. A
TST amplitude ratio of less than 90% was consid-
ered abnormal (18). In the literature, 93% was
established as the lower (2.5 SD) limit of normal
and was used as the diagnostic cut-off value. Because
of the predefined and low number of trials, our
Figure 1. Examples of TST curves as they appear in the report. The first three traces give the response to separate stimulation of ulnar
nerve, plexus brachialis and motor cortex. The following five traces give the TST control and TST test curves. The difference between first
TST control and the TST test curves is filled. In the lowest traces TST test curves (black) and TST control curves (grey) are superimposed.
(A) shows a normal TST amplitude ratio. In (B) TST is abnormal with an amplitude ratio of 69%. In (C) the hand position had changed
between measurements, as can be seen from the shorter duration of the CMAP and the TST response. This artifact was missed initially and
only recognized later (see text). TST amplitude ratio was 87%.

































































cut-off was set lower than recommended initially,
but comparable to that for the first dorsal interosseus
muscle (15,25). Inter-session and inter-reader agree-
ment of the method are reported to be within about
6% (15,25). An example of a normal and an
abnormal TST result is given in Figure 1.
Study design
Between October 2006 and October 2007, conse-
cutive patients were included prospectively provided
that TST could be performed on the same day as the
neurological consultation and EMG. Demographic
data, symptom duration, and the presence of UMN
or LMN signs per region were recorded by a
neurologist (HJS). Disease duration was determined
from when first symptoms were apparent, as indi-
cated in the patient’s history. Nerve conduction
studies and needle EMG were performed by a
neurologist specialized in neuromuscular disease
and motor neuron disorders (HJS) or by a neurology
resident supervised by a clinical neurophysiologist
(MJZ). Arlie House criteria for ALS (3) were applied
by the neurologist (HJS), who did not know the TST
results. All patients with LMN signs only were
classified as having progressive muscular atrophy
(PMA), which overlaps with ‘suspected ALS’ in the
El Escorial classification (2,26,27).
TST was performed and read by a resident in
neurology and clinical neurophysiology (BUK),
together with a technician. The results of neurolo-
gical examination and EMG were not available
during TST. Independent of clinical presentation,
both hands were tested and a TSTamplitude ratio of
less than 90% was considered abnormal (18). If one
or both sides were abnormal, the TST findings were
reported as an indication of UMN deficit in muscles
of the cervical region. At the time of diagnosis, the
neurologist and clinical neurophysiologist were blind
to the results of TST.
If ALS was the initial diagnosis or no alternative
diagnosis was established, patients were followed up
for at least six months. The neurologist re-assessed
the patient and ordered additional tests as required
by the clinical situation. Progression, as expected
from the previous history, was required to confirm
the diagnosis. According to national guidelines,
patients were referred to the closest possible multi-
disciplinary ALS team. In patients that were not re-
assessed at six months at our department, progres-
sion on follow-up by another ALS team was
considered equivalent. The neurologist and the
ALS teams had no access to the TST results at
follow-up.
Outcome measures and statistics
The primary outcome measure was the positivity
rate, i.e. the number of patients that changed in
diagnostic category from ‘PMA/suspected’ or ‘pos-
sible’ or ‘probable laboratory supported’ ALS to
‘probable’ or ‘definite’ on the basis of an abnormal
TST ratio. Progression on follow-up was the refer-
ence standard. We compared the number of patients
who received a diagnosis of ‘probable’ or ‘definite’
ALS on clinical grounds with the number of patients
who would have such a diagnosis after TST. In
clinical trials the effect of treatment can be measured
by the number needed to treat, i.e. the number of
patients that must receive treatment to achieve
one extra favourable outcome (21). Using the same
formula, the number needed to test with TST (NN-
TST) indicates how many patients need to undergo
TST to diagnose one extra case of ALS with the
required certainty (22,28). From the standard error
of the absolute risk difference the 95% confidence
interval of the NN-TST was estimated (29,30). The
NN-TST was calculated for the group of patients in
a low El-Escorial category and for the whole patient
group. NN-TST as a primary outcome measure was
calculated for the intention-to-test population, i.e.
assuming a normal TST ratio in all patients who
have not completed the TST protocol. As a second-
ary outcome, NN-TST was calculated in the patient
group with complete and interpretable TST mea-
surements (‘per protocol’ analysis). From the false-
positive rate the number needed to harm (by
incorrectly diagnosing ALS) with TST was calcu-
lated. Analysis was on the patient level (31). A priori,
no formal calculation of study size was performed.




As summarized in Figure 2, 59 patients consented to
participate. Their demographic characteristics and
disease duration are given in Table I. After work-up
for ALS, 30 patients were diagnosed to have a
variant of motor neuron disease; 10, other central
motor disorders; 17, peripheral nerve disorder; and
two, no neurological disease.
Fifty patients underwent TST. One patient was
excluded from TST because of a cardiac pacemaker,
one patient had a history of ruptured aneurysm that
was treated with a potentially magnetic clip, six
patients stopped early in the recording either due to
the unpleasant sensation of magnetic stimulation or
due to pain from electrical stimulation at Erb’s
point. In one patient severe dyspnoea precluded
TST. Only one patient could not tolerate TST at the
other side after unilateral measurement. His TST
ratio was assumed to be normal for further analysis.
In five patients a TST amplitude ratio could not
be obtained because of peripheral abnormalities.
In three of these patients conduction block was

































































detected and blinding was broken. In another three
patients no MEP and therefore also no TST test
response was obtained. These patients were consid-
ered to have a lesion of the UMNs innervating the
cervical myotomes.
During follow-up, one patient showed no pro-
gression and cramps improved; the diagnosis was
changed from PMA to benign fasciculations and
cramps. Another patient progressed from PMA to
probable ALS. All patients diagnosed with ‘possi-
ble’, ‘probable laboratory supported’, ‘probable’ or
‘definite’ ALS showed some degree of symptom
progression.
Primary outcome measures
In the group with motor neuron disease (n30), 18
patients did not fulfil the criteria for ‘probable’ or
‘definite’ ALS. Of these, 16 patients would have
shifted to a higher diagnostic category if a UMN
lesion in the cervical region were found (Table II). In
four of them TST amplitude ratio was abnormal,
resulting in a positivity rate of 4/18 corresponding to
a NN-TST of 4.5 with a confidence interval not
including infinity (CI 2.433). There were six
patients with UMN signs in only one region of the
body (Table II, ‘probable laboratory supported’). Of
these six patients, five had the UMN signs in the legs
or in the bulbar region only. If TST found evidence
of abnormality in the UMNs supporting the cervical
region, two body regions could be classified as
abnormal, resulting in ‘probable’ ALS. In the sixth
patient, UMN signs were present in the upper
extremity, such that TST would not add any new
information. In four patients TST was performed
‘per protocol’, three times with a TST amplitude
ratio of less than 90% (Table II, first row). For the
whole patient population, four of 59 patients chan-
ged category, resulting in a NN-TST of 15. The
confidence interval was wide and included infinity
(CI 4.8 to  and  to 13).








n = 2 (pacemaker, clip)
Stimulation not tolerated
n = 6 painful/unpleasant
n = 1 dysnoea
TST performed (n = 50)
n = 41 TST amplitude ratio
n = 8 no amplitude ratio obtained
n = 3: no MEP at  100% 
n = 3: conduction block 
n = 2: CMAP < 2.0 mV 
n = 1 unilateral (pain)   
Neurological evaluation 
EMG, imaging etc. 
(blinded to TST)
TST : cervical UMN 
n = 19
area ratio < 90% (16)
no MEP (3)
TST : no cerv UMN 
n = 31
area ratio > 90% (26)
block/no CMAP (5)
Diagnosis (n=59)
n = 30: ALS/PLS/PMA
n = 17: peripheral disorders
n = 10: central disorders
n =   2: no neurological disorder
Diagnosis at follow-up (> 6 month)
Figure 2. Flow diagram summarizing prospective inclusion of patients in the study. The left side gives the diagnostic process. On the right
side the results of the TST study are summarized. Note that the diagnosis and follow-up was blinded for the TST results.

































































In one patient, diagnosed with spondylotic lum-
bosacral polyradiculopathy, a TSTamplitude ratio of
87% was obtained on stimulation of the left side
(Figure 1C). Assuming that a false diagnosis of ALS
may have been given to this patient, the number
needed to harm would be 13 (lower limit of 95% CI,
4.8). In this calculation a ‘worst case’ is considered.
One has to assume that the patient belonged to the per
protocol group of 12 patients and that one extra
patient received a (false-positive) diagnosis of ALS.
We later discovered that the patient’s hand had
changed position between tests, changing the shape
of the action potential.
Secondary outcome measures
Of the 10 patients with ‘probable laboratory sup-
ported’, ‘possible’ or ‘suspected’ ALS and complete
TST data, the positivity rate was 4/10. This means
that four patients changed diagnostic category on the
basis of the TST findings, corresponding to a per
protocol NN-TST of 2.5 (CI 1.410) for low El
Escorial categories (Figure 3). For the group of 50
patients who underwent TST, the per protocol NN-
TST was 13 (CI, 4 to  and  to 12).
Overall, of the 50 TST performed, results were
abnormal in 19 patients. Of these, 14 were in
patients with known or suspected central motor
disorders (Table III, Figure 3). This group included
patients with UMN signs sufficient to diagnose
‘probable’ or ‘definite’ ALS, but also other diseases
that were suspected from history and confirmed by
other parts of the neurological examination or by
neuroimaging. One patient had severe UMN signs in
all regions of the body with only minor LMN
involvement, resulting in a diagnosis of ‘possible’
ALS (Table III). TST added no truly new diagnostic
information in these patients. Except for one false-
positive result (see above), the TST amplitude ratio
was normal in inclusion body myositis and periph-
eral nerve disorders. In two patients, one with
‘probable ALS’ and one with hereditary spastic
paraparesis (HSP), the TST amplitude ratio was
between the two recommended cut-off points of
90% and 93% (15,18).
Discussion
To our knowledge, this is the first prospective, blind
study of the use of TST for the detection of
Table II. TST results in patients in a low category of the El Escorial criteria.
Diagnosis Total (intention-to-test) Could change category TST(per protocol) TST ampl. ratio (mean) TST abnormal
Probable lab. supp. ALS 6 5 4 84% 3
Possible ALS 4 3 3 95% 1
PMA/suspected ALS 8 8 3 105% 0
18 16 10 94% 4







All patients (n59) 58 (2381) 16 (2300) 4/27/27
Definite ALS (2) (51, 60) (8, 35) (2//)
Probable ALS (8) 66 (4071) 9 (544) (2/3/3)
Probable lab. supp. ALS (6) 56 (4681) 18 (637) (/5/1)
Possible ALS (4) 47 (3258) 7 (6114) (/2/2)
PMA/suspected ALS (8) 61 (4577) 25 (5121) (/5/3)
PLS (2) (46, 63) (11, 61) (/1/l)
Vascular (4)* 71 (6474) 100 (26156) (//4)
HSP (4) 38 (2341) 66 (12299) (//4)
MSA (2) (70, 82) (30,132) (//1)
Radiculopathy **(3) 65 (5673) 24 (997) (/2/1)
IBM (3) 63 (5566) 48 (1275) (/1/2)
Neuropathy *** (3) 67 (5975) 9 (611) (/1/2)
MMN (2) (38,49) (15,53) (/2/)
Ulnar neuropathy (2) (59, 70) (4, 50) (/2/)
Benign fasciculations ****(3) 55 (4958) 16 (2,19) (/1/2)
Radiation plexopathy (1) 70 7 (/1/)
No neurological dis. (2) (41,48) (16,60) (/1/1)
* Stroke or extensive white matter lesions on cerebral imaging.
** In one patient myelopathy in combination with radiculopathy.
*** Diabetic, hereditary sensory and motor neuropathy, sequelae of Guillain-Barré syndrome.
**** In one patient benign fasciculations and a history of cerebral hypoxia due to cardiac arrhythmia.

































































subclinical UMN abnormalities in ALS. TST find-
ings were abnormal in about one in five patients who
ultimately developed ALS but who did not meet the
diagnostic criteria for ‘definite’ or ‘probable’ ALS.
The positivity rate was 4/18 and the NN-TST was
4.5 (CI 2.433). The lack of infinity in the con-
fidence interval indicates that TST adds a statisti-
cally significant amount of diagnostic information.
This was also the case for the intention-to-test
analysis, indicating that even with a small number
of drop-outs the statistically significant advantage
was retained.
Previous studies of TST in patients with ALS
(1618,20) were not blinded, so the clinical diag-
nosis may have been influenced by knowledge of
TST results. However, the number of abnormal
TST results in our study was comparable to that
reported in earlier studies, i.e. this study replicates
the diagnostic yield of TST in a blinded setting. As
in open studies, the TST amplitude ratio was more
often abnormal in patients with clear UMN signs,
indicating spectrum bias (17,18,32,33). Thus, TST
is most useful in patients with minor UMN involve-
ment, in whom the findings of the neurological
examination are still normal. In these patients,
TST results are abnormal, but are often relatively
close to the limit of normal. Although most patients
with ‘possible’ or ‘probable laboratory supported’
ALS will eventually develop ALS, it is important to
reduce uncertainty about the diagnosis, both for
patients and their doctors (8,9).
All patients diagnosed with ‘PMA/suspected
ALS’ had a normal TST amplitude ratio. It remains
unclear whether these patients did not have UMN
deficits or whether the technique is not sensitive
enough to detect them. Changing the cut-off value
for an abnormal TST amplitude ratio from 90% to
93% would not solve the problem.
Only the cervical region was investigated in this
study, as TST was performed in intrinsic muscles of
both hands. A TST technique has been described
also for the lower extremity, but its sensitivity in the
diagnosis of ALS is unknown (34).
In contrast to previous studies of TST in ALS,
this study included all patients referred to a motor
neuron disorders clinic. Many of them were ulti-
mately diagnosed with central and peripheral mimics
of ALS. Except for one false-positive result due to
technical problems, no abnormal TST amplitude
ratios were found in patients with peripheral nerve
or muscle disorders, indicating a high specificity.
In some patients with peripheral abnormality, TST
does not give useful results. In case of conduction
block between the wrist and Erb’s point, the study is
diagnostic because ALS is ruled out, but central
conduction itself becomes inaccessible. With severe
loss of motor units resulting in atrophy (CMAP
below 2 mV) or with a single unit pattern, TST
amplitude cannot be interpreted (15,18). This will
not give any diagnostic problems, as all rules for
assessing proximal or central abnormalities in the
context of peripheral abnormalities are well estab-
lished for both nerve conduction studies and the
neurological examination.
As expected, a substantial number of abnormal
results were obtained in patients with different
central motor disorders. Both within and outside
the context of ALS an abnormal TST can be
interpreted almost in the same way as UMN signs.
The probability of ALS is increased by finding a
low TST amplitude ratio, provided that other
pathology within the corticospinal system is ex-
cluded by appropriate neuroimaging. In this sense,
TST is generally not specific for ALS. In particular,
Figure 3. Percentage of abnormal TST amplitude ratios. The
number of abnormal tests is similar in the group with ‘probable/
definite’ ALS and in the group with ‘probable laboratory
supported’ ALS or lower. In the lower diagnostic category, most
abnormal TST results contributed to diagnostic certainty (black
bar).
Table III. TST results in patients with known central motor disorders.
Diagnosis Tested with TST TST amplitude ratio (mean) Abnormal TST amplitude ratio
Definite ALS 2 51% 1
Probable ALS 8 87% 3
Possible ALS 1 34% 1
PLS 1 0% 1
Vascular * 5 70% 3
HSP 4 79% 3
MSA 2 90% 1
Myelopathy 1 84% 1
* Including one patient with benign fasciculations and a history of cerebral hypoxia.

































































this remains true for the differential diagnosis
between ALS and cervical spondylotic myelopathy.
Some additional information can be gained from the
central motor conduction time that is more often
abnormal in the case of compression (17). However,
the contribution of different tests such as conduction
time to the hand muscles, to the trapezius muscle or
needle EMG of the trapezius muscle has not been
studied prospectively (35,36).
In one important aspect a low TST amplitude
ratio differs from clinical UMN signs. The TST
control test is obtained by stimulating the brachial
plexus at Erb’s point. Therefore, an abnormality at
the root or plexus level cannot be differentiated from
abnormality in the central nervous system (15). In
some patients with multifocal motor neuropathy,
isolated proximal conduction block can be demon-
strated with TSTor with stimulation at the root level
(3739). In our study, we considered a misdiagnosis
unlikely, because even in the absence of conduction
block, peripheral nerve conduction studies will
reveal some abnormalities that point to the neuro-
pathy.
Given low diagnostic contribution (high NN-
TST) for the whole patient population, we think that
TST should not be used in every patient referred to
the motor neuron clinic. As defined in our primary
outcome measures, in patients who are classified
with ‘possible’ or as ‘probable laboratory supported’,
ALS TST can contribute to an early diagnosis by
finding subclinical evidence of UMN abnormality.
In the Awaji consensus, the ‘probable laboratory
supported’ category is removed, but the need for a
test of UMN function may actually increase (12).
Using the revised El Escorial criteria together with
the new proposal (Awaji algorithm), results in
increased sensitivity without loss of specificity
(3,13). However, when using the Awaji proposal as
a stand-alone set of criteria (i.e. truly removing
‘laboratory supported’), this reduces sensitivity for
a subgroup of patients, as is best illustrated by an
example: Consider a patient with pseudobulbar
speech, tongue atrophy and EMG abnormalities
including fibrillations in two arm muscles. Accord-
ing to the Airlie House criteria, he or she will be
classified as ‘probable laboratory supported’ ALS.
Using the Awaji criteria alone, the classification
would be ‘possible’ ALS, because only one (bulbar)
region with UMN abnormality was found. This
patient has a three in four chance to have a low
TST amplitude ratio in one of the hands (Table III,
Figure 3). Equivalence of clinical and neurophysio-
logical abnormality in finding LMN abnormality is
one of the principles of the Awaji consensus, but still
awaits validation (40). Extending these principles to
the UMN, we propose that such a patient is
classified as ‘probable’ ALS. A limitation of our
study is the relatively low number of patients. A
replication in a larger, preferentially multicentre
study would both increase the statistical power and
validate our results within the context of the new
Awaji criteria.
In conclusion, TST may be a useful tool with a
high sensitivity for detecting subclinical UMN
abnormalities in suspected ALS. As a result, the
level of diagnostic certainty in the evaluation of ALS
can be increased.
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